Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artificial Intelligence Is Future Of Postmarketing Surveillance, US FDA’s Marks Says

Executive Summary

CBER director’s vision for a national safety surveillance system includes use of AI and natural language processing to enable near-real time signal detection from adverse event reports.

You may also be interested in...



CBER’s Goal To Reach Normal Ops In 2023 Includes Clearing IND, Meeting Backlogs In 2022

CBER director Peter Marks also wants to work on rare disease gene therapy issues and increase hiring before the end of the year.

US FDA Seeks Funding To Modernize Inspection-Related Technology Systems

Head of agency’s inspectorate stresses need to invest in new IT infrastructure for manufacturing site inspections. New FDA Inspectional Affairs Council leads the charge.

Biden Requests US FDA Budget Surge: Pandemic Preparedness Money Would Increase Funding 36%

President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel